GPR35; FFAR1; FFAR4; DRD4; ADRA2C; ADRA2A; ADRA2B; | |
TSHR; NPSR1; CXCR1; NMUR2; | |
ALPL; RECQL; TDP1; PLA2G1B; BLM; ALPI; APOBEC3G; FAAH; CTDSP1; P4HB; TERT; PIK3CA; PIK3CG; PIK3CB; PIK3R1; GLO1; HPGD; MPO; HSD17B1; AKR1B1; HSD17B2; HSD17B10; ALOX15; NQO2; ALDH1A1; ALOX12; GFER; AKR1B10; NOX4; USP2; BRCA1; PYGL; APEX1; POLB; | |
PTPN1; DUSP3; | |
ACHE; GAA; | |
TOP2A; | |
AKT1; MET; CAMK2B; GSK3B; CSNK2A1; DAPK1; SYK; AXL; FLT3; NEK2; MYLK; SRC; IGF1R; PTK2; BRAF; AURKB; AURKA; HASPIN; FLT4; EPHB4; MAP3K8; TEK; PDGFRB; INSR; PLK4; CDK1; MAPK1; EGFR; ERBB2; PIM1; NUAK1; ALK; DYRK2; NEK6; KDR; PLK1; PKN1; | |
CA14; CA5B; CA3; CA7; CA5A; CA9; CA13; CA4; CA6; CA2; CA12; CA1; | |
AR; | |
NR1I2; | |
ESRRA; | |
PPARA; PPARG; PPARD; | |
ESR1; ESR2; | |
KDM4E; | |
MAOA; ALOX5; PTGS1; PTGS2; TYR; XDH; | |
MMP13; MMP3; MMP2; MMP9; MMP1; | |
BACE1; | |
TLR2; | |
AHR; STAT6; HIF1A; NFKB1; TP53; | |
KMT2A; | |
FUT7; | |
ABCC1; ABCG2; | |
SLC22A8; SLC22A6; SLC6A2; SLCO1B1; SLCO1B3; | |
SMAD3; LMNA; FABP4; MAPT; FABP3; FABP5; HBB; THPO; HTT; FABP2; APP; HSPA1A; | |
L3MBTL1; SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | BRCA1 | Breast cancer type 1 susceptibility protein | P38398 | CHEMBL5990 |
Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
Enzyme_unclassified | APOBEC3G | DNA dC->dU-editing enzyme APOBEC-3G | Q9HC16 | CHEMBL1741217 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
Enzyme_unclassified | PIK3CG | PI3-kinase p110-gamma subunit | P48736 | CHEMBL3267 |
Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
Protein Kinase | MYLK | Myosin light chain kinase, smooth muscle | Q15746 | CHEMBL2428 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | BRAF | Serine/threonine-protein kinase B-raf | P15056 | CHEMBL5145 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
Protein Kinase | HASPIN | Serine/threonine-protein kinase haspin | Q8TF76 | CHEMBL1075163 |
Protein Kinase | FLT4 | Vascular endothelial growth factor receptor 3 | P35916 | CHEMBL1955 |
Protein Kinase | EPHB4 | Ephrin type-B receptor 4 | P54760 | CHEMBL5147 |
Protein Kinase | MAP3K8 | Mitogen-activated protein kinase kinase kinase 8 | P41279 | CHEMBL4899 |
Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
Protein Kinase | PDGFRB | Platelet-derived growth factor receptor beta | P09619 | CHEMBL1913 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | PLK4 | Serine/threonine-protein kinase PLK4 | O00444 | CHEMBL3788 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | ERBB2 | Receptor protein-tyrosine kinase erbB-2 | P04626 | CHEMBL1824 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
Protein Kinase | DYRK2 | Dual-specificity tyrosine-phosphorylation regulated kinase 2 | Q92630 | CHEMBL4376 |
Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | PLK1 | Serine/threonine-protein kinase PLK1 | P53350 | CHEMBL3024 |
Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
Protein Phosphatase | DUSP3 | Dual specificity protein phosphatase 3 | P51452 | CHEMBL2635 |
SLC superfamily of solute carriers | SLC22A8 | Solute carrier family 22 member 8 | Q8TCC7 | CHEMBL1641348 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
SLC superfamily of solute carriers | SLC6A2 | Norepinephrine transporter | P23975 | CHEMBL222 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.794E-12 | 2.426E-10 | CYP1A2, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP3A4, NR1I2 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.298E-12 | 3.015E-10 | AXL, EGFR, ERBB2, INSR, MET, NOX4, PDGFRB, PIK3CA, PIK3CB, PIK3CG, PIK3R1, PTK2, SRC, TEK, THPO |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 4.863E-12 | 5.949E-10 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, HBB, XDH |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 6.007E-11 | 6.476E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
BP | GO:0009987; cellular process | GO:0030168; platelet activation | 1.203E-10 | 1.253E-08 | ADRA2A, ADRA2B, ADRA2C, AKT1, AXL, MAPK1, PIK3CA, PIK3CB, PIK3CG, PIK3R1, SRC, SYK |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.183E-10 | 2.181E-08 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.474E-10 | 2.437E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C8, CYP2C9 |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 4.872E-10 | 4.592E-08 | ABCC1, ADRA2A, CA2, CA4, CA9, EGFR, ERBB2, HPGD, SLC22A6, SLC22A8, SLCO1B1, SLCO1B3, TEK, TSHR |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 5.143E-10 | 4.806E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2D6, CYP3A4 |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 4.493E-09 | 3.792E-07 | EGFR, ERBB2, INSR, KDR, SYK |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.535E-09 | 3.798E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 1.626E-08 | 1.255E-06 | IGF1R, INSR, PIK3CA, PIK3CB, PIK3R1 |
CC | GO:0044464; cell part | GO:0005829; cytosol | 1.968E-08 | 1.498E-06 | AHR, AKR1B1, AKR1B10, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, APOBEC3G, APP, AR, AURKA, AURKB, BLM, BRAF, CA1, CA13, CA2, CA3, CA7, CAMK2B, CDK1, CSNK2A1, DUSP3, DYRK2, EPHB4, ERBB2, FABP2, FABP3, FABP4, FABP5, FLT3, GFER, GLO1, GSK3B, HBB, HIF1A, HPGD, HSD17B1, HSPA1A, HTT, KMT2A, LMNA, MAP3K8, MAPK1, MAPT, MYLK, NEK2, NEK6, NFKB1, NQO2, PIK3CA, PIK3CB, PIK3CG, PIK3R1, PIM1, PKN1, PLA2G1B, PLK1, PLK4, PPARG, PTK2, PTPN1, PYGL, SMAD3, SMN1, SMN2, SRC, STAT6, SYK, TP53, TYR, XDH |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.768E-08 | 2.057E-06 | CYP1A2, CYP2C8, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 3.007E-08 | 2.205E-06 | ADRA2B, ALK, CDK1, DRD4, INSR, MAPK1, PIK3CB, PKN1, PLA2G1B, PTPN1, SYK |
MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 3.196E-08 | 2.327E-06 | ADRA2A, ADRA2C, AHR, AURKA, AXL, BRAF, EGFR, ERBB2, HIF1A, NFKB1, P4HB, PIK3R1, PPARD, PPARG, SMAD3, TLR2, TOP2A, TP53, TYR |
MF | Unclassified; | GO:0004872; receptor activity | 4.101E-08 | 2.928E-06 | ADRA2A, ADRA2B, ADRA2C, AHR, ALK, AR, AXL, CXCR1, DRD4, EGFR, EPHB4, ERBB2, ESR1, ESR2, ESRRA, FFAR1, FFAR4, FLT3, FLT4, GPR35, HPGD, IGF1R, INSR, KDR, MET, NMUR2, NPSR1, NR1I2, PDGFRB, PPARA, PPARD, PPARG, TEK, TLR2, TSHR |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 5.251E-08 | 3.700E-06 | AURKB, CA2, CA7, EGFR, HIF1A, HTT, MAPK1, NEK2, NPSR1, PIK3CB, PLA2G1B, PTGS2, SYK |
MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 7.105E-08 | 4.865E-06 | EGFR, ERBB2, MET, PDGFRB, PIK3CA, PIK3CB, PIK3CG, PIK3R1 |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 9.341E-08 | 6.258E-06 | ALOX15, APP, BRAF, EGFR, FFAR4, FLT4, KDR, NOX4, PDGFRB, SRC, TEK, THPO |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.117E-07 | 7.259E-06 | EGFR, IGF1R, INSR, KDR, PTK2, SRC, SYK |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 1.298E-07 | 8.363E-06 | AHR, AKR1B1, AKT1, ALOX5, APEX1, AR, AURKA, AURKB, BLM, BRCA1, CAMK2B, CDK1, CSNK2A1, CTDSP1, DUSP3, DYRK2, ESR1, ESR2, ESRRA, FABP5, GSK3B, HIF1A, HPGD, HSPA1A, HTT, KMT2A, L3MBTL1, LMNA, MAPK1, NEK2, NEK6, NFKB1, NQO2, NR1I2, NUAK1, PIM1, PKN1, PLK1, POLB, PPARA, PPARD, PPARG, RECQL, SMAD3, SMN1, SMN2, SRC, STAT6, TERT, TOP2A, TP53, USP2 |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 1.420E-07 | 9.065E-06 | AXL, FLT4, KDR, PIK3CA, PIK3CB, PIK3R1, PTK2, SRC |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.486E-07 | 9.380E-06 | ALOX12, ALOX15, ALOX5, HPGD, PTGS2 |
MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 1.729E-07 | 1.082E-05 | ABCG2, ACHE, ADRA2A, ADRA2C, AKT1, APOBEC3G, BLM, CAMK2B, FLT3, FLT4, HPGD, KMT2A, MAPT, NFKB1, NQO2, PTGS2, PYGL, SLC22A6, SMAD3, TERT, TOP2A, TYR, XDH |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 2.056E-07 | 1.261E-05 | AKT1, HIF1A, LMNA, P4HB, PPARD, PTGS2, SRC, TERT, TP53 |
MF | GO:0005488; binding | GO:0051379; epinephrine binding | 3.093E-07 | 1.825E-05 | ADRA2A, ADRA2B, ADRA2C, DRD4 |
BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 3.264E-07 | 1.921E-05 | ADRA2A, ADRA2B, ADRA2C, AKT1, INSR, SRC |
MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 5.578E-07 | 3.122E-05 | ADRA2A, ADRA2B, ADRA2C |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 6.696E-07 | 3.673E-05 | CYP1A1, PDGFRB, POLB, PPARG, TP53 |
BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 8.492E-07 | 4.561E-05 | ADRA2A, AKT1, FFAR1, HIF1A, INSR, NOX4, PIK3CA, PIK3R1, PPARG, PYGL |
BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 1.040E-06 | 5.498E-05 | AKT1, EGFR, HBB, INSR, PTGS2, SMAD3 |
BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 1.556E-06 | 7.968E-05 | APP, CDK1, EGFR, MAPK1, PIK3R1, PTGS2, SMAD3, TLR2 |
BP | GO:0008152; metabolic process | GO:0046854; phosphatidylinositol phosphorylation | 1.681E-06 | 8.454E-05 | EGFR, ERBB2, MET, PDGFRB, PIK3CA, PIK3CB, PIK3CG, PIK3R1 |
BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 2.140E-06 | 1.052E-04 | AKT1, AURKA, AURKB, BLM, BRCA1, CSNK2A1, DYRK2, L3MBTL1, NUAK1, TP53 |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 2.194E-06 | 1.069E-04 | ADRA2A, AURKB, CA2, CA7, EGFR, HIF1A, HTT, KDR, MAPK1, NEK2, NPSR1, PIK3CB, PLA2G1B, PTGS2, SRC, SYK |
BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 2.218E-06 | 1.071E-04 | ADRA2A, ADRA2B, ADRA2C |
BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 2.218E-06 | 1.071E-04 | ADRA2A, ADRA2B, ADRA2C |
BP | GO:0050896; response to stimulus | GO:0043627; response to estrogen | 2.416E-06 | 1.154E-04 | BRCA1, CA2, ESR1, MAPK1, PDGFRB, PPARG, TEK |
BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 2.552E-06 | 1.213E-04 | BRCA1, CYP1B1, FLT4, HIF1A, PTGS2 |
CC | GO:0032991; macromolecular complex | GO:0043235; receptor complex | 2.942E-06 | 1.384E-04 | ABCG2, ADRA2A, AHR, APP, EGFR, ERBB2, FLT4, IGF1R, INSR, SMAD3, SYK, TLR2, TSHR |
BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 3.068E-06 | 1.437E-04 | AKT1, CYP1B1, DAPK1, GSK3B, HPGD, HTT, MAPT, MMP9, NOX4, PDGFRB, PIK3CB, PPARG, PTGS2, SMAD3, SRC, TOP2A, TP53, XDH |
MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 3.704E-06 | 1.684E-04 | AXL, IGF1R, INSR, PDGFRB, PIK3R1 |
BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 4.415E-06 | 1.962E-04 | FLT3, PDGFRB, PTK2, SRC, TEK |
BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 4.488E-06 | 1.982E-04 | AKT1, FABP3, FFAR1, PPARG, PTGS2, SRC, TLR2 |
BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 5.193E-06 | 2.266E-04 | CYP19A1, FFAR4, NFKB1, PPARA, PPARD, PPARG, SMAD3, TEK |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 5.229E-06 | 2.277E-04 | AKT1, CYP1A2, EGFR, MAPK1, MMP9 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 5.510E-06 | 2.367E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0009987; cellular process | GO:0038084; vascular endothelial growth factor signaling pathway | 5.764E-06 | 2.466E-04 | FLT3, FLT4, KDR, PDGFRB |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 6.156E-06 | 2.613E-04 | AHR, CSNK2A1, HIF1A, KDR, MAPT |
BP | GO:0023052; signaling | GO:0050806; positive regulation of synaptic transmission | 7.576E-06 | 3.136E-04 | APP, BRAF, CA2, CA7, DRD4, EGFR, MAPK1, PTGS2 |
BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 7.599E-06 | 3.140E-04 | AR, CDK1, ESR1, ESR2, ESRRA, NR1I2, PPARA, PPARD, PPARG |
MF | Unclassified; | GO:0032403; protein complex binding | 9.667E-06 | 3.834E-04 | ACHE, ADRA2A, APEX1, EGFR, FLT3, IGF1R, INSR, KDR, MMP13, MMP9, P4HB, PIK3R1, PLK1, PPARA, PTPN1, SMAD3, SRC, SYK, TLR2, TSHR |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 9.921E-06 | 3.914E-04 | CYP2A6, CYP2C19, CYP2C8, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.095E-05 | 4.274E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.121E-05 | 4.365E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1, STAT6 |
MF | GO:0005488; binding | GO:0019838; growth factor binding | 1.284E-05 | 4.958E-04 | EGFR, ERBB2, FLT4, IGF1R, INSR, KDR, PDGFRB, TEK |
MF | Unclassified; | GO:0099600; transmembrane receptor activity | 1.332E-05 | 5.097E-04 | ADRA2A, ADRA2B, ADRA2C, ALK, AXL, CXCR1, DRD4, EGFR, EPHB4, ERBB2, FFAR1, FFAR4, FLT3, FLT4, GPR35, HPGD, IGF1R, INSR, KDR, MET, NMUR2, NPSR1, PDGFRB, PPARG, TEK, TSHR |
BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 1.407E-05 | 5.357E-04 | AKT1, HIF1A, HSPA1A, MMP9, PTGS2, PTPN1, SRC |
BP | GO:0009987; cellular process | GO:0038128; ERBB2 signaling pathway | 1.680E-05 | 6.241E-04 | EGFR, ERBB2, PIK3CA, PIK3R1, SRC |
BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 1.772E-05 | 6.552E-04 | FLT3, KDR, PDGFRB, PPARD, PTK2, TEK |
CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 1.796E-05 | 6.605E-04 | ABCC1, ADRA2A, ADRA2B, ADRA2C, ALK, APP, AXL, BACE1, DRD4, EPHB4, FFAR1, FFAR4, FLT3, FLT4, GPR35, IGF1R, INSR, KDR, MET, NPSR1, SLC22A6, SLC22A8, SLC6A2, SLCO1B1, SLCO1B3, TEK, TLR2, TSHR |
BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 1.905E-05 | 6.926E-04 | CYP1A1, CYP2A6, CYP2D6 |
MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 1.905E-05 | 6.926E-04 | FLT3, FLT4, KDR |
MF | GO:0003824; catalytic activity | GO:0035005; 1-phosphatidylinositol-4-phosphate 3-kinase activity | 1.905E-05 | 6.926E-04 | PIK3CA, PIK3CB, PIK3CG |
MF | GO:0098772; molecular function regulator | GO:0030235; nitric-oxide synthase regulator activity | 1.905E-05 | 6.926E-04 | AKT1, EGFR, ESR1 |
MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 1.981E-05 | 7.130E-04 | AHR, ESR1, PPARA, TERT |
BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 2.248E-05 | 8.013E-04 | APP, AR, CYP1B1, ERBB2, FABP3, HSPA1A, KMT2A, LMNA, NOX4, PKN1, PPARD, PPARG, PTGS2, SMAD3, TERT, TLR2, TP53, XDH |
MF | GO:0003824; catalytic activity | GO:0004712; protein serine/threonine/tyrosine kinase activity | 2.432E-05 | 8.641E-04 | AKT1, AURKA, AURKB, DYRK2, MAPK1 |
MF | GO:0005488; binding | GO:0002039; p53 binding | 2.489E-05 | 8.826E-04 | BLM, GSK3B, HIF1A, HTT, NUAK1, TP53 |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 2.876E-05 | 1.012E-03 | HIF1A, MMP1, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 2.952E-05 | 1.035E-03 | HPGD, MMP2, MMP9, TERT |
BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 2.952E-05 | 1.035E-03 | HIF1A, SMAD3, TERT, TP53 |
BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 3.030E-05 | 1.061E-03 | ADRA2A, ADRA2B, ADRA2C |
BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 3.166E-05 | 1.101E-03 | MMP1, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0065007; biological regulation | GO:0008217; regulation of blood pressure | 3.447E-05 | 1.191E-03 | ADRA2B, AR, HBB, PPARA, PPARG, PTGS1, PTGS2, SMAD3 |
BP | GO:0009987; cellular process | GO:0071216; cellular response to biotic stimulus | 3.616E-05 | 1.246E-03 | AXL, GSK3B, NFKB1, PPARD, SRC, SYK, TLR2, TP53 |
CC | GO:0043226; organelle | GO:0044454; nuclear chromosome part | 3.745E-05 | 1.282E-03 | APEX1, AR, AURKA, AURKB, BLM, BRCA1, CDK1, CSNK2A1, ESR1, PLK1, PPARD, SMAD3, STAT6, TERT, TP53 |
BP | Unclassified; | GO:0042993; positive regulation of transcription factor import into nucleus | 3.816E-05 | 1.305E-03 | APP, PIK3R1, PTGS2, SMAD3, TLR2 |
MF | GO:0005215; transporter activity | GO:0015347; sodium-independent organic anion transmembrane transporter activity | 4.234E-05 | 1.427E-03 | SLC22A6, SLC22A8, SLCO1B1, SLCO1B3 |
BP | GO:0032502; developmental process | GO:0045766; positive regulation of angiogenesis | 4.362E-05 | 1.468E-03 | ALOX12, BRCA1, CYP1B1, HIF1A, KDR, PTGS2, TEK, TERT |
BP | GO:0065007; biological regulation | GO:0031647; regulation of protein stability | 4.436E-05 | 1.488E-03 | AURKA, HSPA1A, HTT, MAPK1, PIK3R1, PLK1, SMAD3, SRC, TERT, USP2 |
BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 4.517E-05 | 1.511E-03 | APP, EGFR, MAPT |
BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 4.517E-05 | 1.511E-03 | BLM, RECQL, TP53 |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 5.008E-05 | 1.662E-03 | FABP2, FABP3, FABP4, FABP5 |
MF | GO:0005488; binding | GO:0001085; RNA polymerase II transcription factor binding | 5.136E-05 | 1.700E-03 | AHR, AR, ESR1, GSK3B, PPARA, SMAD3, TP53 |
BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 5.716E-05 | 1.860E-03 | AKR1B1, AKT1, AR, EGFR, PPARG, SRC |
BP | GO:0008152; metabolic process | GO:0051974; negative regulation of telomerase activity | 6.414E-05 | 2.051E-03 | PPARG, SRC, TP53 |
BP | GO:0051179; localization | GO:0042908; xenobiotic transport | 6.414E-05 | 2.051E-03 | ABCC1, ABCG2, NR1I2 |
BP | GO:0065007; biological regulation | GO:0043006; activation of phospholipase A2 activity by calcium-mediated signaling | 6.819E-05 | 2.141E-03 | EGFR, NMUR2 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 6.819E-05 | 2.141E-03 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 6.819E-05 | 2.141E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 6.819E-05 | 2.141E-03 | PTGS1, PTGS2 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 6.819E-05 | 2.141E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 6.819E-05 | 2.141E-03 | ALOX12, ALOX15 |
MF | GO:0005488; binding | GO:0003682; chromatin binding | 7.547E-05 | 2.348E-03 | APEX1, AR, CDK1, EGFR, ESR1, KMT2A, L3MBTL1, MPO, NFKB1, PKN1, PPARG, SMAD3, TOP2A, TP53 |
CC | GO:0043226; organelle | GO:0005876; spindle microtubule | 7.626E-05 | 2.362E-03 | AURKA, AURKB, CDK1, PLK1, POLB |
BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 7.847E-05 | 2.417E-03 | CYP1A2, EGFR, ESR1, ESRRA, HPGD, PDGFRB, PTGS2 |
BP | GO:0008152; metabolic process | GO:0046320; regulation of fatty acid oxidation | 7.950E-05 | 2.438E-03 | AKT1, FABP3, PPARA, PPARG |
BP | GO:0051179; localization | GO:0043252; sodium-independent organic anion transport | 7.950E-05 | 2.438E-03 | SLC22A6, SLC22A8, SLCO1B1, SLCO1B3 |
MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 7.950E-05 | 2.438E-03 | AKT1, MAPT, PTPN1, TP53 |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 8.003E-05 | 2.441E-03 | HIF1A, MMP1, MMP13, MMP2, MMP3, MMP9 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 8.003E-05 | 2.441E-03 | AR, CYP3A4, ESR1, ESR2, ESRRA, HSD17B1 |
BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 8.765E-05 | 2.651E-03 | AR, CYP19A1, ESR1 |
MF | GO:0005488; binding | GO:0034452; dynactin binding | 8.765E-05 | 2.651E-03 | GSK3B, HTT, MAPT |
BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 9.122E-05 | 2.729E-03 | CDK1, EGFR, IGF1R, INSR, PLA2G1B |
BP | GO:0009987; cellular process | GO:0038096; Fc-gamma receptor signaling pathway involved in phagocytosis | 1.057E-04 | 3.076E-03 | MAPK1, PIK3CA, PIK3CB, PIK3R1, PTK2, SRC, SYK |
BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 1.077E-04 | 3.114E-03 | ALPL, AXL, CYP1A1, CYP1A2, HPGD, MPO, NFKB1, PPARD, PTGS2, SRC |
BP | GO:0008283; cell proliferation | GO:0033598; mammary gland epithelial cell proliferation | 1.162E-04 | 3.318E-03 | ESR1, MAPK1, STAT6 |
CC | GO:0043226; organelle | GO:0051233; spindle midzone | 1.198E-04 | 3.389E-03 | APP, AURKA, AURKB, PLK1 |
BP | GO:0032501; multicellular organismal process | GO:0003007; heart morphogenesis | 1.361E-04 | 3.804E-03 | EPHB4, GAA, INSR, PTK2 |
BP | GO:0009987; cellular process | GO:0060326; cell chemotaxis | 1.460E-04 | 4.039E-03 | ABCC1, CXCR1, PDGFRB, PIK3CA, PIK3CB, PIK3CG, PLA2G1B, SYK |
BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 1.501E-04 | 4.126E-03 | CYP19A1, HSD17B1, HSD17B2 |
BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 1.538E-04 | 4.219E-03 | ACHE, EGFR, FFAR1, HIF1A, PLA2G1B, PPARD, SRC, SYK, TLR2 |
BP | Unclassified; | GO:0045907; positive regulation of vasoconstriction | 1.538E-04 | 4.219E-03 | ADRA2C, AKT1, EGFR, PTGS2 |
BP | GO:0009987; cellular process | GO:1901215; negative regulation of neuron death | 1.632E-04 | 4.460E-03 | AKT1, AXL, BRAF, GSK3B, HIF1A, PIK3CA, PPARA, TERT |
BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 1.652E-04 | 4.506E-03 | DRD4, PPARA, PPARG, TOP2A, TP53, USP2 |
BP | GO:0065007; biological regulation | GO:0051092; positive regulation of NF-kappaB transcription factor activity | 1.677E-04 | 4.569E-03 | ALK, APP, AR, HSPA1A, NFKB1, PLA2G1B, TLR2 |
BP | GO:0008152; metabolic process | GO:0033138; positive regulation of peptidyl-serine phosphorylation | 1.746E-04 | 4.746E-03 | AKT1, APP, BRAF, EGFR, PIK3CA, PTGS2 |
BP | GO:0032502; developmental process | GO:0060065; uterus development | 1.899E-04 | 5.100E-03 | CYP19A1, ESR1, SRC |
BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 2.026E-04 | 5.350E-03 | MMP1, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 2.034E-04 | 5.350E-03 | APP, TLR2 |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 2.034E-04 | 5.350E-03 | CYP2D6, CYP3A4 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.034E-04 | 5.350E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 2.034E-04 | 5.350E-03 | ALOX15, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 2.034E-04 | 5.350E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 2.034E-04 | 5.350E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 2.034E-04 | 5.350E-03 | ALOX12, ALOX15 |
BP | GO:0040011; locomotion | GO:0014911; positive regulation of smooth muscle cell migration | 2.172E-04 | 5.665E-03 | NOX4, PDGFRB, SRC, TERT |
MF | GO:0005488; binding | GO:0003684; damaged DNA binding | 2.338E-04 | 6.061E-03 | APEX1, BLM, BRCA1, POLB, TP53 |
BP | GO:0032501; multicellular organismal process | GO:0045780; positive regulation of bone resorption | 2.359E-04 | 6.084E-03 | CA2, EGFR, SYK |
BP | GO:0009987; cellular process | GO:0008630; intrinsic apoptotic signaling pathway in response to DNA damage | 2.507E-04 | 6.430E-03 | BRCA1, DYRK2, PIK3R1, POLB, TP53 |
BP | GO:0051179; localization | GO:0032368; regulation of lipid transport | 2.667E-04 | 6.786E-03 | AKT1, CYP19A1, NFKB1, PPARA, PPARG, SYK |
BP | GO:0022414; reproductive process | GO:0007566; embryo implantation | 2.687E-04 | 6.820E-03 | MMP2, MMP9, PPARD, PTGS2 |
BP | GO:0032502; developmental process | GO:0048638; regulation of developmental growth | 2.747E-04 | 6.964E-03 | AKT1, APP, AR, CDK1, INSR, MAPT, PIK3CA, PIM1, PPARD, PTK2 |
MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 2.805E-04 | 7.095E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, NQO2, XDH |
BP | GO:0009987; cellular process | GO:1901992; positive regulation of mitotic cell cycle phase transition | 2.872E-04 | 7.197E-03 | APEX1, APP, CDK1, CYP1A1, TERT |
BP | GO:0009987; cellular process | GO:2000811; negative regulation of anoikis | 2.886E-04 | 7.197E-03 | PIK3CA, PTK2, SRC |
BP | GO:0050896; response to stimulus | GO:0070920; regulation of production of small RNA involved in gene silencing by RNA | 2.886E-04 | 7.197E-03 | EGFR, ESR1, TERT |
BP | GO:0008152; metabolic process | GO:0019318; hexose metabolic process | 2.892E-04 | 7.197E-03 | AKR1B1, AKT1, ALDH1A1, FUT7, GAA, PIK3CA, PPARD |
CC | GO:0016020; membrane | GO:0005901; caveola | 3.069E-04 | 7.612E-03 | INSR, MAPK1, PTGS2, SLC22A6, SRC |
CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 3.224E-04 | 7.978E-03 | ACHE, AKR1B1, APEX1, APP, AURKA, CA4, EGFR, ERBB2, HSPA1A, HTT, NOX4, PPARG, SRC, TYR, USP2 |
BP | GO:0022610; biological adhesion | GO:0033628; regulation of cell adhesion mediated by integrin | 3.285E-04 | 8.109E-03 | CYP1B1, PIK3CG, PTK2, SYK |
MF | GO:0005488; binding | GO:0001046; core promoter sequence-specific DNA binding | 3.413E-04 | 8.408E-03 | ESR1, ESR2, KMT2A, PPARG, STAT6, TP53 |
BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 3.483E-04 | 8.502E-03 | CYP1A1, PPARD, PPARG |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 3.483E-04 | 8.502E-03 | AURKB, MAPK1, NEK2 |
BP | GO:0065007; biological regulation | GO:0060249; anatomical structure homeostasis | 3.951E-04 | 9.495E-03 | AKR1B1, APEX1, BLM, GAA, HIF1A, KMT2A, NOX4, SRC, TERT |
BP | GO:0032502; developmental process | GO:0031214; biomineral tissue development | 3.962E-04 | 9.502E-03 | ALOX15, ALPL, MMP13, PPARA, PTGS2 |
BP | GO:0032501; multicellular organismal process | GO:0032640; tumor necrosis factor production | 4.047E-04 | 9.608E-03 | APP, TLR2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.047E-04 | 9.608E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 4.047E-04 | 9.608E-03 | ESR1, ESR2 |
MF | GO:0005488; binding | GO:0051425; PTB domain binding | 4.047E-04 | 9.608E-03 | APP, INSR |
MF | GO:0005488; binding | GO:0005497; androgen binding | 4.047E-04 | 9.608E-03 | ALDH1A1, AR |
BP | GO:0065007; biological regulation | GO:0048872; homeostasis of number of cells | 4.120E-04 | 9.731E-03 | AXL, FLT3, HIF1A, KMT2A, PKN1, POLB |
BP | GO:0051179; localization | GO:0071459; protein localization to chromosome, centromeric region | 4.154E-04 | 9.778E-03 | AURKB, CDK1, HASPIN |
BP | GO:0008152; metabolic process | GO:0051000; positive regulation of nitric-oxide synthase activity | 4.154E-04 | 9.778E-03 | AKT1, HIF1A, TERT |
BP | GO:0008152; metabolic process | GO:0032928; regulation of superoxide anion generation | 4.154E-04 | 9.778E-03 | EGFR, MAPT, SYK |
BP | GO:0009987; cellular process | GO:0072422; signal transduction involved in DNA damage checkpoint | 4.213E-04 | 9.886E-03 | AURKA, BRCA1, CDK1, PLK1, TP53 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.055E-23 | 5.544E-20 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.191E-17 | 8.675E-15 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, HBB |
MF | GO:0005488; binding | GO:0005524; ATP binding | 5.114E-17 | 1.856E-14 | ABCC1, ABCG2, AKT1, ALK, AURKA, AURKB, AXL, BLM, BRAF, CAMK2B, CDK1, CSNK2A1, DAPK1, DYRK2, EGFR, EPHB4, ERBB2, FLT3, FLT4, GSK3B, HASPIN, HSPA1A, IGF1R, INSR, KDR, MAP3K8, MAPK1, MET, MYLK, NEK2, NEK6, NUAK1, PDGFRB, PIK3CA, PIK3CB, PIK3CG, PIM1, PKN1, PLK1, PLK4, PTK2, PYGL, RECQL, SRC, SYK, TEK, TOP2A, TP53 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 5.582E-16 | 1.413E-13 | ALPI, APOBEC3G, AR, BLM, BRCA1, CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, ESRRA, GLO1, KMT2A, L3MBTL1, MMP1, MMP13, MMP2, MMP3, MMP9, NQO2, NR1I2, PPARA, PPARD, PPARG, PTPN1, SMAD3, TP53 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.471E-15 | 9.935E-13 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
MF | GO:0005488; binding | GO:0020037; heme binding | 9.639E-15 | 1.962E-12 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, HBB, MPO, NOX4, PTGS1, PTGS2, SRC |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 7.087E-14 | 1.235E-11 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, HBB, NOX4 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.190E-17 | 8.883E-16 | GSK3B; FLT3; PIK3CB; PIK3R1; PTGS2; HIF1A; EGFR; PIK3CG; IGF1R; ERBB2; AKT1; MAPK1; PDGFRB; SMAD3; MMP1; DAPK1; MMP2; BRAF; MMP9; NFKB1; PTK2; AR; PIK3CA; PPARG; MET; TP53; PPARD |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.346E-17 | 8.883E-16 | CAMK2B; SRC; MMP2; BRAF; PIK3R1; PIK3CB; HIF1A; ESR1; MMP9; PTK2; EGFR; PIK3CG; IGF1R; PIK3CA; ERBB2; KDR; AKT1; MAPK1; TP53; MET; TLR2 |
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 2.701E-22 | 5.349E-20 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 4.138E-16 | 2.048E-14 | PDGFRB; GSK3B; BRAF; PIK3CB; PIK3R1; EGFR; NFKB1; PIK3CG; IGF1R; AR; PIK3CA; ERBB2; AKT1; MAPK1; TP53 |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 4.588E-14 | 1.298E-12 | PDGFRB; GSK3B; SYK; INSR; FLT4; PIK3R1; BRCA1; PIK3CB; PTK2; EGFR; NFKB1; PIK3CG; IGF1R; PIK3CA; KDR; AKT1; MAPK1; TEK; PKN1; TP53; MET; TLR2 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 5.861E-15 | 2.321E-13 | PDGFRB; FLT3; PIK3CB; PIK3R1; HIF1A; EGFR; PIK3CG; PIK3CA; ERBB2; AKT1; MAPK1; TP53; MET |
hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 4.340E-14 | 1.298E-12 | PDGFRB; GSK3B; SRC; FLT4; BRAF; PIK3R1; PIK3CB; PTK2; EGFR; PIK3CG; MYLK; IGF1R; PIK3CA; ERBB2; KDR; AKT1; MAPK1; MET |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.265E-13 | 2.783E-12 | PDGFRB; CAMK2B; PIK3CA; AKT1; MAPK1; BRAF; PIK3CB; PIK3R1; TP53; EGFR; PIK3CG; IGF1R |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 9.205E-14 | 2.278E-12 | CAMK2B; INSR; PIK3R1; PIK3CB; HIF1A; EGFR; NFKB1; PIK3CG; IGF1R; PIK3CA; ERBB2; AKT1; MAPK1; TEK |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.536E-13 | 3.040E-12 | SMAD3; PIK3CA; ERBB2; AKT1; MAPK1; BRAF; PIK3CB; PIK3R1; TP53; EGFR; NFKB1; PIK3CG |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 2.061E-13 | 3.710E-12 | CAMK2B; GSK3B; SRC; BRAF; PIK3CB; PIK3R1; EGFR; PTK2; PIK3CG; PIK3CA; ERBB2; AKT1; MAPK1 |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 2.764E-13 | 4.560E-12 | GSK3B; PIK3CA; ERBB2; AKT1; MAPK1; BRAF; PIK3CB; PIK3R1; TP53; EGFR; PIK3CG |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 3.859E-13 | 5.877E-12 | PDGFRB; PIK3CA; AKT1; MAPK1; BRAF; PIK3CB; PIK3R1; TP53; MET; EGFR; PIK3CG; IGF1R |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 6.629E-13 | 9.375E-12 | ALK; PIK3CA; ERBB2; AKT1; MAPK1; BRAF; PIK3CB; PIK3R1; TP53; EGFR; PIK3CG |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.148E-12 | 1.337E-11 | SRC; MMP2; PIK3R1; PIK3CB; ESR1; MMP9; EGFR; ESR2; PIK3CG; PIK3CA; AKT1; MAPK1; HSPA1A |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 8.158E-13 | 1.010E-11 | PIK3CA; FLT3; PIM1; AKT1; MAPK1; BRAF; PIK3CB; PIK3R1; NFKB1; PIK3CG; PPARD |
hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 1.420E-11 | 1.406E-10 | PDGFRB; SRC; INSR; FLT4; BRAF; PIK3R1; PIK3CB; EGFR; PIK3CG; IGF1R; PIK3CA; KDR; AKT1; MAPK1; TEK; MET |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 5.765E-12 | 6.341E-11 | APP; MAOA; ALOX15; BRAF; ALOX12; CYP2C19; PTGS2; PTGS1; CYP2C9; CYP2C8; CYP2D6; ALOX5; MAPK1 |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 4.276E-11 | 3.848E-10 | PDGFRB; PLA2G1B; INSR; FLT4; PIK3R1; PIK3CB; EGFR; NFKB1; PIK3CG; IGF1R; PIK3CA; KDR; AKT1; MAPK1; TEK; MET |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.206E-11 | 1.256E-10 | GSK3B; PIK3CA; SRC; AKT1; MAPK1; PIK3CB; PIK3R1; ESR1; NFKB1; ESR2; PIK3CG |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 7.324E-13 | 9.668E-12 | MMP1; DAPK1; SRC; MMP2; ERBB2; MAPK1; BRAF; MMP9; TP53; EGFR |
hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 5.245E-11 | 4.327E-10 | PLK4; SMAD3; INSR; PLK1; BRAF; PIK3R1; PIK3CB; EGFR; PIK3CG; IGF1R; PIK3CA; AKT1; MAPK1 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.705E-10 | 1.298E-09 | SMAD3; SRC; PIK3R1; PIK3CB; MMP9; NFKB1; PIK3CG; PIK3CA; AKT1; MAPK1; STAT6; TP53; TLR2 |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 2.099E-11 | 1.979E-10 | FABP4; PIK3CA; INSR; AKT1; PIK3CB; PIK3R1; PTGS2; TSHR; PIK3CG; PTGS1 |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 5.138E-11 | 4.327E-10 | PIK3CA; SRC; KDR; AKT1; MAPK1; PIK3CB; PIK3R1; PTGS2; PTK2; PIK3CG |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 6.084E-11 | 4.819E-10 | GSK3B; SMAD3; PIK3CA; AKT1; MAPK1; BRAF; PIK3CB; PIK3R1; TP53; PIK3CG |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 3.261E-10 | 2.306E-09 | SMAD3; PIK3CA; AKT1; MAPK1; BRAF; PIK3CB; PIK3R1; TP53; NFKB1; PIK3CG |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 7.556E-10 | 4.987E-09 | GSK3B; PIK3CA; AKT1; MAPK1; BRAF; PIK3R1; PIK3CB; PPARA; TP53; EGFR; NFKB1; PIK3CG |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.311E-09 | 8.111E-09 | PIK3CA; MMP3; AKT1; MAPK1; MAP3K8; PIK3R1; PIK3CB; PTGS2; MMP9; NFKB1; PIK3CG |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.188E-09 | 7.587E-09 | PTPN1; GSK3B; PIK3CA; INSR; AKT1; PIK3R1; PIK3CB; PYGL; PPARA; NFKB1; PIK3CG |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 3.745E-10 | 2.557E-09 | PTPN1; SMAD3; CSNK2A1; SRC; INSR; ERBB2; MAPK1; MET; EGFR; IGF1R |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 2.785E-09 | 1.532E-08 | GSK3B; PIK3CA; SRC; AKT1; MAPK1; PIK3R1; PIK3CB; TP53; ESR1; HIF1A; PIK3CG |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 3.332E-09 | 1.783E-08 | CAMK2B; GSK3B; PIK3CA; AKT1; MAPK1; BRAF; PIK3R1; PIK3CB; TP53; NFKB1; PIK3CG |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.026E-10 | 1.486E-09 | HSD17B1; ALOX5; INSR; HSD17B2; CYP1A1; CYP1B1; PTGS2; CYP19A1; IGF1R |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 8.327E-09 | 4.021E-08 | SMAD3; PIK3CA; MMP2; PIM1; AKT1; MAPK1; PIK3R1; PIK3CB; NFKB1; PIK3CG |
hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 6.196E-09 | 3.146E-08 | PIK3CA; PLK1; CDK1; AKT1; MAPK1; BRAF; PIK3R1; PIK3CB; PIK3CG; IGF1R |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 4.111E-09 | 2.142E-08 | PIK3CA; INSR; AKT1; PPARG; PIK3CB; PIK3R1; TP53; NFKB1; PIK3CG; IGF1R |
hsa05162 | Measles_Homo sapiens_hsa05162 | 1.253E-08 | 5.905E-08 | GSK3B; PIK3CA; CSNK2A1; AKT1; PIK3R1; PIK3CB; TP53; NFKB1; PIK3CG; HSPA1A; TLR2 |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 2.684E-09 | 1.518E-08 | PIK3CA; AKT1; MAPK1; BRAF; PIK3CB; PIK3R1; MET; HIF1A; PIK3CG |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 2.277E-08 | 1.002E-07 | PDGFRB; PIK3CA; SYK; CXCR1; INSR; AKT1; MAPK1; PIK3R1; PIK3CB; EGFR; PIK3CG |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.511E-09 | 9.069E-09 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; CYP2C19; PTGS2; PTGS1 |
hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.575E-08 | 7.250E-08 | PTPN1; GSK3B; PIK3CA; INSR; AKT1; MAPK1; BRAF; PIK3R1; PIK3CB; PYGL; PIK3CG |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 6.711E-09 | 3.322E-08 | GSK3B; PIK3CA; SYK; AKT1; MAPK1; PIK3CB; PIK3R1; NFKB1; PIK3CG |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 2.369E-08 | 1.020E-07 | HPGD; KMT2A; FLT3; MMP3; PPARG; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 3.621E-08 | 1.463E-07 | GSK3B; PIK3CA; CXCR1; SRC; AKT1; MAPK1; BRAF; PIK3R1; PIK3CB; NFKB1; PTK2; PIK3CG |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 8.473E-08 | 3.050E-07 | GSK3B; SYK; CSNK2A1; PIK3CA; CDK1; AKT1; PIK3R1; PIK3CB; TP53; NFKB1; PIK3CG; HSPA1A |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 3.760E-08 | 1.489E-07 | PIK3CA; ALOX5; AKT1; MAPK1; PIK3R1; PIK3CB; NFKB1; PIK3CG; HSPA1A; TLR2 |
hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 5.175E-08 | 1.970E-07 | PIK3CA; SYK; SRC; AKT1; MAPK1; PIK3R1; PIK3CB; PIK3CG; MYLK; PTGS1 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.235E-07 | 4.215E-07 | PDGFRB; ABCC1; BRCA1; PTGS2; MMP9; EGFR; NFKB1; PIK3CA; ERBB2; PIM1; CYP1B1; MAPK1; TP53; MET |
hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 1.049E-07 | 3.709E-07 | PIK3CA; INSR; AKT1; MAPK1; PIK3R1; PIK3CB; ADRA2C; ADRA2B; ADRA2A; PIK3CG; MYLK |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 2.910E-08 | 1.200E-07 | PIK3CA; AKT1; PIK3CB; PIK3R1; PTGS2; TP53; NFKB1; PTK2; PIK3CG |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.905E-08 | 8.574E-08 | CYP2C9; CYP2C8; CYP2A6; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 5.546E-07 | 1.716E-06 | PLA2G1B; MAOA; ALOX15; AKR1B1; ALOX12; PYGL; PTGS2; CYP2C19; CYP3A4; CYP19A1; HSD17B10; PTGS1; FUT7; HSD17B1; ALOX5; HSD17B2; XDH; GAA; TYR; CYP2C9; CYP2C8; CYP2A6; AKR1B10; CYP1A2; ALDH1A1; CYP1A1; ALPL; ALPI |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.193E-07 | 4.144E-07 | PDGFRB; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; HIF1A; EGFR; PIK3CG |
hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 5.866E-07 | 1.787E-06 | CAMK2B; PIK3CA; SRC; MAPK1; PIK3R1; PIK3CB; PTGS2; EGFR; PIK3CG; MYLK |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.813E-07 | 5.886E-07 | PIK3CA; AKT1; MAPK1; MAP3K8; PIK3R1; PIK3CB; NFKB1; PIK3CG; TLR2 |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.538E-07 | 5.075E-07 | SMAD3; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; NFKB1; PIK3CG; TLR2 |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 2.530E-08 | 1.066E-07 | PIK3CA; AKT1; MAPK1; BRAF; PIK3CB; PIK3R1; HIF1A; PIK3CG |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.538E-07 | 5.075E-07 | GSK3B; PIK3CA; AKT1; MAPK1; MAP3K8; PIK3R1; PIK3CB; NFKB1; PIK3CG |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 8.217E-07 | 2.393E-06 | POLB; SYK; PIK3CA; SRC; CDK1; MAPK1; PIK3R1; PIK3CB; TP53; NFKB1; PIK3CG |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 6.124E-07 | 1.837E-06 | CAMK2B; PIK3CA; AKT1; MAPK1; BRAF; PIK3R1; PIK3CB; PPARA; NFKB1; TSHR; PIK3CG |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.170E-06 | 3.255E-06 | PDGFRB; POLB; GSK3B; SMAD3; TERT; PIK3CA; AKT1; PIK3R1; PIK3CB; TP53; NFKB1; PIK3CG |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 5.250E-07 | 1.650E-06 | ABCC1; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; TP53; NFKB1; PIK3CG |
hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 4.260E-08 | 1.654E-07 | PIK3CA; INSR; AKT1; PIK3CB; PIK3R1; PIK3CG; HSPA1A; IGF1R |
hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 1.254E-06 | 3.401E-06 | PDGFRB; PIK3CA; SRC; MAPK1; BRAF; PIK3R1; PIK3CB; PTK2; EGFR; PIK3CG; MYLK |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.919E-06 | 5.079E-06 | PIK3CA; LMNA; AKT1; MAPK1; PIK3R1; PIK3CB; TP53; NFKB1; PIK3CG |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.174E-06 | 3.255E-06 | PIK3CA; SYK; AKT1; MAPK1; PPARG; PIK3R1; PIK3CB; NFKB1; PIK3CG |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 7.780E-08 | 2.853E-07 | CYP2C9; CYP2C8; CYP2A6; MAOA; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 2.159E-06 | 5.625E-06 | GSK3B; SMAD3; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; PIK3CG; IGF1R |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 6.797E-06 | 1.641E-05 | PDGFRB; DUSP3; AKT1; MAPK1; BRAF; MAP3K8; MAPT; TP53; EGFR; NFKB1; HSPA1A |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 3.587E-06 | 8.878E-06 | GSK3B; PIK3CA; INSR; AKT1; PIK3R1; PIK3CB; PPARA; NFKB1; PIK3CG |
hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 7.780E-08 | 2.853E-07 | FABP2; FABP3; FABP4; FABP5; MMP1; PPARG; PPARA; PPARD |
hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 3.093E-06 | 7.753E-06 | CAMK2B; ACHE; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; PIK3CG |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.189E-05 | 2.770E-05 | GSK3B; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; NFKB1; PIK3CG; HSPA1A |
hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 4.106E-05 | 9.033E-05 | PIK3CA; THPO; PIM1; AKT1; STAT6; PIK3R1; PIK3CB; PIK3CG |
hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 1.167E-03 | 2.265E-03 | SMAD3; CXCR1; SRC; KDR; MET; EGFR; HSPA1A; IGF1R |
hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 7.065E-06 | 1.685E-05 | PIK3CA; INSR; AKT1; PPARG; PIK3R1; PIK3CB; PIK3CG; IGF1R |
hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 1.350E-03 | 2.595E-03 | PDGFRB; CXCR1; THPO; FLT3; FLT4; KDR; MET; EGFR |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 5.848E-04 | 1.182E-03 | CAMK2B; SYK; SRC; AKT1; MAPK1; NFKB1; TLR2 |
hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 1.913E-04 | 3.987E-04 | CAMK2B; PIK3CA; AKT1; MAPK1; PIK3R1; PIK3CB; PIK3CG |
hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 7.021E-03 | 1.207E-02 | GPR35; NMUR2; ADRA2C; ADRA2B; ADRA2A; DRD4; TSHR |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 9.980E-04 | 1.956E-03 | CAMK2B; GSK3B; SMAD3; CSNK2A1; TP53; PPARD |
hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 1.498E-02 | 2.411E-02 | PDGFRB; CAMK2B; ERBB2; EGFR; MYLK |
hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 1.081E-04 | 2.276E-04 | PIK3CA; SYK; MAPK1; BRAF; PIK3R1; PIK3CB; PIK3CG |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 2.349E-03 | 4.388E-03 | BACE1; APP; GSK3B; MAPK1; MAPT; HSD17B10 |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.667E-02 | 2.599E-02 | CSNK2A1; CDK1; TP53; NFKB1; TLR2 |
hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 6.006E-05 | 1.293E-04 | CAMK2B; AR; PLK1; CDK1; MAPK1; AURKA; IGF1R |
hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 1.382E-05 | 3.182E-05 | CAMK2B; PIK3CA; SRC; ALOX12; PIK3R1; PIK3CB; PIK3CG |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 3.227E-03 | 5.917E-03 | GSK3B; SMAD3; PLK1; CDK1; TP53 |
hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 3.575E-03 | 6.495E-03 | GSK3B; MAPK1; MET; PTK2; EPHB4 |
hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 3.822E-03 | 6.880E-03 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 9.786E-06 | 2.307E-05 | PIK3CA; SYK; AKT1; MAPK1; PIK3CB; PIK3R1; PIK3CG |
hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 4.609E-05 | 1.003E-04 | PIK3CA; MMP2; PIK3R1; PIK3CB; MMP9; PTK2; PIK3CG |
hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 1.578E-05 | 3.591E-05 | PIK3CA; PIK3R1; PIK3CB; NFKB1; PTK2; PIK3CG; TLR2 |
hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 1.583E-02 | 2.501E-02 | PLA2G1B; MAPK1; BRAF; MYLK |
hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 1.184E-06 | 3.255E-06 | PIK3CA; SYK; AKT1; MAPK1; PIK3CB; PIK3R1; PIK3CG |
hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 8.538E-03 | 1.433E-02 | CAMK2B; GSK3B; MAPK1; TYR |
hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 8.836E-03 | 1.470E-02 | CAMK2B; AKT1; PYGL; PPARA |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 8.227E-04 | 1.629E-03 | CAMK2B; SRC; MMP2; MAPK1; EGFR |
hsa04070 | Phosphatidylinositol signaling system_Homo sapiens_hsa04070 | 7.963E-03 | 1.348E-02 | PIK3CA; PIK3R1; PIK3CB; PIK3CG |
hsa05323 | Rheumatoid arthritis_Homo sapiens_hsa05323 | 5.915E-03 | 1.039E-02 | MMP1; MMP3; TEK; TLR2 |
hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 6.636E-03 | 1.153E-02 | SYK; CSNK2A1; PTGS2; NFKB1 |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 3.174E-02 | 4.637E-02 | MAPK1; PKN1; NFKB1 |
hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 3.017E-06 | 7.658E-06 | PIK3CA; SRC; PIK3CB; PIK3R1; MET; PTK2; PIK3CG |
hsa04540 | Gap junction_Homo sapiens_hsa04540 | 7.065E-04 | 1.413E-03 | PDGFRB; SRC; CDK1; MAPK1; EGFR |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.924E-06 | 5.079E-06 | CYP2C9; CYP2A6; CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.475E-09 | 1.441E-08 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 8.672E-07 | 2.488E-06 | CYP2C9; CYP2C8; CYP2A6; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 2.153E-02 | 3.255E-02 | CAMK2B; CA2; MYLK |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 2.797E-03 | 5.176E-03 | MAPK1; PTGS2; NFKB1; TLR2 |
hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 1.861E-02 | 2.878E-02 | AKT1; PPARA; NFKB1 |
hsa00562 | Inositol phosphate metabolism_Homo sapiens_hsa00562 | 1.932E-02 | 2.965E-02 | PIK3CA; PIK3CB; PIK3CG |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.925E-07 | 1.253E-06 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 1.592E-02 | 2.501E-02 | CAMK2B; MAPK1; BRAF |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.528E-02 | 2.440E-02 | SRC; MAPK1; NFKB1 |
hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 1.232E-02 | 2.017E-02 | MAPK1; BRAF; IGF1R |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 2.225E-05 | 5.006E-05 | SLCO1B1; CA2; SLCO1B3; SLC22A8; CYP3A4; ABCG2 |
hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 1.828E-03 | 3.447E-03 | SMAD3; STAT6; NFKB1; TLR2 |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 2.137E-04 | 4.408E-04 | CXCR1; SRC; MET; EGFR; NFKB1 |
hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 9.725E-03 | 1.605E-02 | NFKB1; TLR2; HSPA1A |
hsa05144 | Malaria_Homo sapiens_hsa05144 | 7.072E-03 | 1.207E-02 | HBB; MET; TLR2 |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 5.929E-03 | 1.039E-02 | CYP2A6; CYP3A4; XDH |
hsa05020 | Prion diseases_Homo sapiens_hsa05020 | 3.185E-02 | 4.637E-02 | MAPK1; HSPA1A |
hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 2.218E-06 | 5.704E-06 | PIK3CA; INSR; MAPK1; PIK3CB; PIK3R1; PIK3CG |
hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 6.258E-07 | 1.849E-06 | PIK3CA; INSR; MAPK1; PIK3CB; PIK3R1; PIK3CG |
hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 3.185E-02 | 4.637E-02 | MAOA; TYR |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 2.856E-02 | 4.251E-02 | POLB; APEX1 |
hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 2.696E-02 | 4.045E-02 | AKR1B10; AKR1B1 |
hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 3.355E-02 | 4.848E-02 | AKR1B10; AKR1B1 |
hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 1.958E-02 | 2.983E-02 | MAPK1; EGFR |
hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 2.904E-05 | 6.460E-05 | PIK3CA; AKT1; PIK3CB; PIK3R1; PIK3CG |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.741E-03 | 3.314E-03 | AKR1B10; GAA; AKR1B1 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 2.881E-04 | 5.880E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.441E-02 | 2.339E-02 | CA2; CA4 |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 8.016E-05 | 1.707E-04 | MAPK1; BRAF; PPARG; TP53 |
hsa00790 | Folate biosynthesis_Homo sapiens_hsa00790 | 5.434E-03 | 9.692E-03 | ALPL; ALPI |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 4.966E-06 | 1.214E-05 | CYP2A6; CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; SRC; EGFR; EGFR; ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR; KDR |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2; MYLK |
NA: NA | Dyslipidemia | NA | PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; ADRA2C; SLC6A2; PPARG; PPARD; PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA; FFAR1; INSR |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK; PIK3CG; PIK3CG; ERBB2; PLK1 |
A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; TYR |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; PPARD |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; PPARG; PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; PIK3CG; PIK3CG; FFAR1; PTGS2; INSR; NFKB1; PPARG; PPARG; PPARD |
L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
NA: NA | Enthesopathy | NA | PIK3CG |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; ACHE; SLC6A2; FAAH; CYP3A4 |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; FAAH |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | PIK3CG; CYP2C9 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A; SLC6A2; SLC6A2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; INSR; TLR2; ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
NA: NA | Upper abdominal bloating | NA | ACHE |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; MMP9 |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
C00-D49: Neoplasms | Liver cancer | C22 | TERT; IGF1R; KDR |
C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3; ESR1 |
C00-D49: Neoplasms | Late-stage non-small cell lung cancer | C33-C34 | EPHB4 |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE; BRAF |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; ADRA2C; SLC6A2; SLC6A2; SLC6A2; SLC6A2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; ALOX5; PTGS1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; GSK3B; PTPN1; FFAR1; PDGFRB; INSR; PPARG |
C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1; EGFR; ERBB2 |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | SLC6A2 |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Beta thalassemia | D56.1 | HBB |
C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
C00-D49: Neoplasms | Metastatic melanoma | C43 | BRAF; BRAF |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ESRRA; ALOX5; PIK3CG; PTGS2; PTGS2; TEK; MMP1 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ESRRA; ALOX5; ALOX5; SYK; SYK; PTGS2; ERBB2; ADRA2C |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
NA: NA | Miosis during ocular surgery | NA | PTGS1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH; ADRA2C; SLC6A2 |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TERT; EGFR; EGFR; EGFR; TP53; KDR; KDR |
A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
C00-D49: Neoplasms | HER2-positive urogenital cancer | NA | ERBB2 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | PDGFRB; APP |
C00-D49: Neoplasms | Breast cancer | C50 | AR; TERT; PIK3CG; FLT3; FLT3; CA9; NQO2; IGF1R; INSR; CYP19A1; CDK1; EGFR; EGFR; EGFR; ERBB2; ERBB2; ERBB2; ESR1; ESR1; KDR; KDR; KDR |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; KDR |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | ERBB2; KDR |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
C00-D49: Neoplasms | Diffuse large B-cell lymphoma | C83.3 | PIK3CG |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
C00-D49: Neoplasms | Cancer | C00-C96 | AR; AKT1; MET; GSK3B; CA1; CSNK2A1; SYK; PIK3CA; PIK3CG; FLT3; FLT3; CA9; MMP2; NQO2; ACHE; PTGS2; SRC; IGF1R; PTK2; BRAF; BRAF; AURKA; FLT4; EPHB4; TEK; HIF1A; CDK1; MAPK1; MMP9; NFKB1; EGFR; ERBB2; ERBB2; PIM1; TLR2; TP53; PIK3CB; ESR1; ESR1; KDR; PLK1; APP |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | SLC6A2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
C00-D49: Neoplasms | Melanoma | C43 | TERT; BRAF; EGFR; TLR2; TYR; KDR; KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
NA: NA | Menopausal disorder | NA | ESR1 |
NA: NA | Edema | NA | CA2 |
I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC; EGFR; EGFR; ERBB2 |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE; ADRA2C |
NA: NA | GIST | NA | FLT3 |
NA: NA | Geographic retinal atrophy | NA | APP |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; PTGS2; XDH; PPARG |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | PIK3CG; KDR |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; MMP1 |
C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; PIK3CG; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; SLC6A2; FAAH |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
NA: NA | Gonorrheal vaginitis | NA | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; FLT4; EGFR |
C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; PIK3CG; PIK3CG; CA9; INSR; HIF1A; EGFR; ERBB2; PLK1 |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ESRRA; ALOX5; SYK; MMP3; PTGS2; PTGS2; PTGS2; PTGS2; TYR; MMP1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; PPARD; ESR1 |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PIK3CA; PTK2; BRAF; AURKA; TP53 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA; MMP2; PTGS1; ESR1 |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1; PIK3CG |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; SRC; AURKB; TP53 |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; MMP2; EGFR; EGFR; KDR; KDR; KDR; KDR |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; ERBB2 |
NA: NA | Joint and muscular pain | NA | PTGS2 |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; TEK |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | SLC6A2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; IGF1R; ESR1; ESR1 |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
NA: NA | HIV infections | NA | AHR |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; TERT; FLT3; MMP2; PTGS2; EGFR; TLR2; KDR; PLK1 |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
C00-D49: Neoplasms | CLL | NA | FLT3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; CA2 |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2; PPARG |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2 |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13; SYK; PIK3CG; PTGS1; PTGS2; FAAH |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR; ERBB2; KDR; KDR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C; SLC6A2 |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TEK; TLR2; KDR |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3; EGFR |
C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; TERT; PIK3CG; FLT3; FLT4; EGFR; ERBB2; TLR2; ESR1; PLK1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PIK3CG; MMP3 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; FLT4; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
C00-D49: Neoplasms | Neuroendocrine cancer | C7A | SLC6A2 |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; NPSR1; ESR1; APP |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS1; PTGS2; PTGS2; ADRA2B |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B; SRC |
A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARG; PPARD |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; AXL; PTGS2; IGF1R; IGF1R; PDGFRB; EGFR; EGFR; KDR |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ESRRA; ADRA2C |
L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK; EGFR |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | NR1I2; ALOX5; PPARD |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK; PIK3CB |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; DRD4 |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1 |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
C00-D49: Neoplasms | Neuroblastoma | C74.1, C74.9, C75.4, C75.5, D35.0, D35.5, D35.6, D44.6, D44.7 | SLC6A2 |
C00-D49: Neoplasms | Glioma | C71 | PIK3CG; EGFR; EGFR; KDR; APP |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; PTGS2; PTGS2 |
H00-H59: Diseases of the eye and adnexa | Retinal venous occlusion | H34.8 | ERBB2 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT; FLT3; FLT3; AURKB; AURKA; TP53; TP53; PLK1 |
K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; PTGS1; IGF1R; MMP9; EGFR; EGFR; ERBB2; TP53; KDR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; SRC; ESR1 |
NA: NA | Colour dead tissues | NA | PTPN1 |
C00-D49: Neoplasms | Colon cancer | C50 | ALPL; FLT3; EGFR |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
C00-D49: Neoplasms | Solid tumors | NA | BRAF |
C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; SYK; PIK3CA; PIK3CG; FLT3; CA9; MMP2; SRC; IGF1R; PTK2; AURKB; AURKA; FLT4; TEK; PDGFRB; HIF1A; MAPK1; MMP9; EGFR; ERBB2; TLR2; TP53; PIK3CB; KDR; KDR; KDR; PLK1; PLK1; TOP2A |
C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; TERT; SRC; IGF1R |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
NA: NA | Male hypogonadism | NA | AR |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; CYP19A1; PPARG |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
NA: NA | Angioedema | NA | PIK3CG |
A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; BRAF; KDR |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; ESR1; ESR1 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; MMP13; ACHE; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; IGF1R; INSR; CDK1; ADRA2C; ADRA2A; SLC6A2; FAAH; ESR1 |
C00-D49: Neoplasms | Haematological malignancies | C81-C86 | AURKA |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
C00-D49: Neoplasms | AML | NA | FLT3; KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; SYK |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; GSK3B; MAPT; ACHE; ACHE; ACHE; PTGS2; INSR; ADRA2C; PPARG; PPARG; APP |
S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
NA: NA | Postmenopausal disorder | NA | ESR1 |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; PIK3CG; PIK3CG; AURKA; PLK1 |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
C00-D49: Neoplasms | Endometrial cancer | C54.1 | PIK3CG; PIK3CG |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ADRA2C; ADRA2B |
K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vascular restinosis following vascular graft surgery | T82.858A | FLT4 |